$NXTC

Nextcure Inc

  • NASDAQ
  • Biotechnology
  • Health Technology

PRICE

$4.76 β–²3.03%

Last Close

VOLUME

110,957

DAY RANGE

4.64 - 4.785

52 WEEK

3.25 - 9.18

Join Discuss about NXTC with like-minded investors

profile
@thegiz18 #ivtrades
recently

$NXTC upgrade, $19 target

102 Replies 13 πŸ‘ 14 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$NXTC has some clear air above yesterdays highs

70 Replies 11 πŸ‘ 7 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$NXTC finally breaking free from prior call out

131 Replies 13 πŸ‘ 15 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$NXTC has been catching some bids, above 12.80 has lots of clear air

120 Replies 15 πŸ‘ 10 πŸ”₯

TR
@TraderJack #ivtrades
recently

$NXTC is not vaccine play

46 Replies 9 πŸ‘ 12 πŸ”₯

TR
@TraderJack #ivtrades
recently

Still in $BMRN, $NBIX, $AZN, $NXTC, $EBS, and $PFE. It is ok for them down today

121 Replies 6 πŸ‘ 15 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$NXTC upgraded with $17 price target after Mondays bloodbath

147 Replies 8 πŸ‘ 13 πŸ”₯

profile
@thegiz18 #ivtrades
recently

$NXTC getting spanked, announced not moving forward on a stage 2 trial on one of their cancer drug candidates, down nearly 30% premarket

101 Replies 12 πŸ‘ 8 πŸ”₯

Key Metrics

Market Cap

132.08 M

Beta

0

Avg. Volume

200.35 K

Shares Outstanding

27.75 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IOβ„’ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.

CEO: Michael Richman

Website:

HQ: 9000 Virginia Manor Rd Ste 200 Beltsville, 20705-4214 Maryland

Related News